News

News 24.09.2024 Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has received three grants totaling more than CHF 1.3 million from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association. The funding from Target ALS and...

News 19.09.2024 September 18, 2024. ZURICH, Switzerland and NEWTON, Massachusetts, US. –GlobeNewswire– Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.  The agreement focuses on the co-marketing and co-selling of Biognosys’ Spectronaut software with...

News 18.09.2024 Sep 17, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-inclass therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing...

News 31.08.2024 August 29, 2024. ZURICH, Switzerland and Newton, Massachusetts, US. — GlobeNewswire — Biognosys, a global leader in next-generation proteomics solutions for drug discovery and development, announced today the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids. NULISA is a proprietary high-sensitivity proteomics platform developed by...

News 28.08.2024 Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces that Alex Bastian has joined the Company as VP Commercial Strategy. Alex Bastian is an experienced commercial leader in the biotech...